A 52-Week, Open-Label Study of Oral Olanzapine With a Randomized Behavioral Weight Intervention in Adolescents With Schizophrenia or Bipolar I Disorder

New Research Poster Presentation 4.27
A 52-Week, Open-Label Study of Oral Olanzapine With a Randomized Behavioral Weight Intervention in Adolescents With Schizophrenia or Bipolar I Disorder

Friday, October 24, 2014 9:30 AM

Holland C. Detke, PhD, Lilly Research Laboratories, Indianapolis, IN

Melissa P. DelBello, MD, MS, Psychiatry, University of Cincinnati, Cincinnati, OH

John Landry, MS, Eli Lilly and Company, Toronto, ON, Canada

Ralf W. Dittmann, MD, Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany